Neurotoxicity is the limiting side effect of the anticancer agent oxaliplatin. A tangled panel of
symptoms, sensory loss, paresthesia, dysesthesia, and pain may be disabling for patients …

Background: A major clinical issue affecting 10-40% of cancer patients treated with
oxaliplatin is severe peripheral neuropathy with symptoms including cold sensitivity and …

Oxaliplatin, a platinum-based chemotherapeutic agent, has become a standard treatment for
advanced colorectal cancer. The dose-limiting toxicity of this compound is the development …

We describe an animal model of nociceptive sensory neuropathy induced by repeat
intravenous administration of oxaliplatin in which treated animals partly reproduce the …

Oxaliplatin is a third-generation platinum-based chemotherapeutic drug. Although its
efficacy against colorectal cancer is well known, peripheral neuropathy that develops during …

Chemotherapy-induced peripheral neuropathy (CIPN) is a common, dose limiting, and long-
lasting side effect of chemotherapy treatment. Unfortunately, no treatment has proven …

Although platinum-based cancer chemotherapies produce painful peripheral neuropathy as
dose-limiting side effects, there are important differences in the pain syndromes produced by …

Background Peripheral neuropathy is the major dose-limiting side effect of cisplatin and
oxaliplatin, and there are currently no effective treatments available. The aim of this study …

Spinal microglia are widely recognized as activated by and contributing to the generation
and maintenance of inflammatory and nerve injury related chronic pain; whereas the role of …

Background Neuropathic pain is observed in patients as chemotherapeutic oxaliplatin is
used to treat metastatic digestive tumors; however, the mechanisms responsible for …